Search Results 101-110 of 23137 for B cell lymphomas
Study of Brentuximab Vedotin Combined With RCHOP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) · Overview · Participation ...
It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma. Venetoclax ...
These models and tools have been developed by the lab or in collaboration with lab members. Prognostic models. Diffuse large B-cell lymphoma. Newly diagnosed.
... B-Cell Non-Hodgkin Lymphomas. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More information ...
... B-cell non-Hodgkin lymphoma (NHL) subtypes of diffuse large B-cell lymphoma (DLBCL) and Grade 3 follicular lymphoma (FL3). Additionally, the pharmacokinetic ...
A Study to Compare Tisagenlecleucel vs. Standard of Care in Adult Patients with Aggressive B-cell Non-Hodgkin Lymphoma · Share · Facebook · Twitter.
B-cell lymphomas are a heterogeneous group of neoplasms that arise from lymphocytes and produce tumors in the lymph nodes, lymphatic organs and extranodal ...
... cell lymphoma, a subset of B-cell lymphoma. It was also approved in February 2014 for use in CLL, following a study of the agent alone in patients with very ...
The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia ...
The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.